Associated Genetic Biomarkers
NCI Definition: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. 
Leukemias most frequently harbor alterations in ASXL1, DNMT3A, TET2, NPM1, and ETV6 .
ASXL1 Mutation, DNMT3A Mutation, TET2 Mutation, NPM1 Mutation, and NPM1 Exon 12 Mutation are the most common alterations in leukemia .
There are 15 clinical trials for leukemia, of which 12 are open and 3 are completed or closed. Of the trials that contain leukemia as an inclusion criterion, 10 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open).
ERBB2, ABL1, and IDH1 are the most frequent gene inclusion criteria for leukemia clinical trials .
Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most common interventions in leukemia clinical trials.
Significant Genes in Leukemia
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.